Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Common Equity (2016 - 2018)

Historic Common Equity for Armata Pharmaceuticals (ARMP) over the last 6 years, with Q3 2018 value amounting to $8.8 million.

  • Armata Pharmaceuticals' Common Equity fell 984.93% to $8.8 million in Q3 2018 from the same period last year, while for Sep 2018 it was $8.8 million, marking a year-over-year decrease of 984.93%. This contributed to the annual value of $7.7 million for FY2017, which is 2048.75% down from last year.
  • Armata Pharmaceuticals' Common Equity amounted to $8.8 million in Q3 2018, which was down 984.93% from $11.6 million recorded in Q2 2018.
  • Armata Pharmaceuticals' 5-year Common Equity high stood at $408.5 million for Q1 2018, and its period low was -$34.0 million during Q1 2014.
  • For the 5-year period, Armata Pharmaceuticals' Common Equity averaged around $27.1 million, with its median value being $9.7 million (2016).
  • In the last 5 years, Armata Pharmaceuticals' Common Equity tumbled by 5410.07% in 2017 and then soared by 604417.87% in 2018.
  • Armata Pharmaceuticals' Common Equity (Quarter) stood at $3.4 million in 2014, then skyrocketed by 269.92% to $12.7 million in 2015, then fell by 23.53% to $9.7 million in 2016, then fell by 20.49% to $7.7 million in 2017, then grew by 13.78% to $8.8 million in 2018.
  • Its last three reported values are $8.8 million in Q3 2018, $11.6 million for Q2 2018, and $408.5 million during Q1 2018.